Your session is about to expire
← Back to Search
HOPO 14-1 for Chemical Toxicity Safety Study
Study Summary
This trial studies the safety and effectiveness of a new drug, HOPO 14-1, given as a single, oral dose up to 7500 mg to healthy participants.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Logistics
Participation is compensated
You will be compensated for participating in this trial.
Who is running the clinical trial?
Media Library
- I have not had a fever or serious infection in the last week.I have trouble swallowing pills.I have received an organ or bone marrow transplant.I have not had chelation therapy in the last year.I haven't taken any experimental drugs recently.I have had health issues found through exams or tests.I understand the study's requirements and agree to follow them.I am in good health overall, according to my recent medical exams.I haven't used laxatives, antibiotics, or antacids in the last week.My weight is between 50kg and 110kg, or if over, my BMI is ≤ 40.I've felt very lightheaded or faint, had balance problems, or extreme tiredness within 2 days after taking medication.I have not had a blood transfusion in the last 3 months.My weight is between 50kg and 110kg, or if over, my BMI is ≤ 40.I am in good health overall, according to my recent medical exams.
- Group 1: Cohort 1: 100 mg
- Group 2: Cohort 2: 200 mg
- Group 3: Cohort 3: 500 mg
- Group 4: Cohort 4: 1200 mg
- Group 5: Cohort 5: 2500 mg
- Group 6: Cohort 6: 5000 mg
- Group 7: Cohort 7: 7500 mg
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is this clinical study enrolling individuals aged 55 and over?
"According to the prerequisites outlined for this trial, individuals aged 18 and older but younger than 65 are eligible to participate."
Is there any danger associated with administering Cohort 1: 100 mg to patients?
"Due to the lack of data concerning Cohort 1: 100 mg's safety and efficacy, our team ranked its risk level at a low score of 1."
Is recruitment presently taking place for this trial?
"Affirmative. Records on clinicaltrials.gov verify that this scientific trial, which was first uploaded on March 15th 2023, is actively recruiting patients. Around 42 individuals must be enlisted from a single medical facility."
How many individuals have been recruited to participate in this experiment?
"Affirmative. According to clinicaltrials.gov, this study is still open for recruitment and was first published on March 15th 2023 with the latest update occurring May 22nd of that same year. At present, 42 patients are needed from a single location."
Who has the potential to be accepted into this research protocol?
"This clinical trial is looking for 42 adults between 18 and 65 years of age with chemical toxicity. Applicants must demonstrate their understanding of the study protocol, provide written consent, use contraception if applicable, be in good health according to medical history and tests results, pass a drug test unless prescribed medication can explain any positives on the urine or blood screen, weigh at least 50 kg but less than 110 kg (if over that weight then BMI should not exceed 40)."
Who else is applying?
What state do they live in?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
What questions have other patients asked about this trial?
Why did patients apply to this trial?
Share this study with friends
Copy Link
Messenger